ARTICLE

Localization of the Organic Anion Transporting Polypeptide 2 (Oatp2) in Capillary Endothelium and Choroid Plexus Epithelium of Rat Brain

Correspondence to: Peter J. Meier, Div. of Clinical Pharmacology and Toxicology, Dept. of Medicine, University Hospital, CH-8091 Zurich, Switzerland.

	Summary

Top Summary Introduction Materials and Methods Results Discussion Literature Cited

In this study we investigated the distribution of a recently cloned polyspecific organic anion transporting polypeptide (Oatp2) in rat brain by nonradioactive in situ hybridization histochemistry and immunofluorescence microscopy. The results demonstrate that Oatp2 is expressed in brain capillary and in plexus epithelial cells. At the blood–brain barrier (BBB), Oatp2 expression could be co-localized with the endothelial marker vWF (von Willebrand factor) but not with the astrocyte marker GFAP (glial fibrillary acidic protein). In choroid plexus epithelial cells, Oatp2 could be localized to the basolateral cell pole, whereas the first member of the Oatp gene family of membrane transporters to be cloned (Oatp1) co-localized with the ₁-subunit of Na,K-ATPase at the apical plasma membrane domain. Because Oatp1 and Oatp2 have been previously shown to mediate transmembrane transport of a wide variety of amphipathic organic compounds, including many drugs and other xenobiotics, the histochemical localization of Oatp2 at the BBB and of Oatp1 and Oatp2 in the choroid plexus imply a role for these transporters in the active exchange of amphipathic solutes between the blood, brain, and cerebrospinal fluid compartments. (J Histochem Cytochem 47:1255–1263, 1999)

Key Words: drug transport, organic anion transporter, blood–brain barrier, choroid plexus

	Introduction

Top Summary Introduction Materials and Methods Results Discussion Literature Cited

The blood–brain barrier (BBB) endothelium and the choroid plexus epithelium control the exchange of many endogenous and exogenous compounds between the blood plasma and the brain tissue and cerebrospinal fluid, respectively. Several specific and nonspecific transport systems have been described that permit access of essential nutrients and antioxidants to brain tissue and/or prevent the intracerebral accumulation of potentially neurotoxic compounds (Spector and Johanson 1989 ; Abbott and Romero 1996 ). Transport systems with broad substrate specificities include (a) probenecid sensitive "renal-like" efflux systems for transport of organic anions such as penicillin, p-aminohippurate, methotrexate, and zidovudine from brain and cerebrospinal fluid into blood plasma (Wong et al. 1993 ), (b) saturable glutathione (GSH) transport pathways at the BBB and the choroid plexus, (Anderson et al. 1989 ; Kannan et al. 1990 , Kannan et al. 1992 ; Zlokovic et al. 1994 ), (c) one or several "liver-like" organic anion transporter(s) at the choroid plexus (Barany 1973a , Barany 1973b ), and (d) the P-glycoprotein (P-gp) or multidrug-resistance [mdr1a/b (rodents)/MDR1 (humans)] efflux pump at the luminal (blood) side of BBB endothelial cells (Beaulieu et al. 1997 ), where it mediates ATP-dependent efflux of a variety of amphipathic compounds into blood plasma (Abbott and Romero 1996 ). In mdr1a (-/-) knockout mice, failure to express P-gp at the BBB results in highly increased brain concentrations of a range of drugs, including digoxin, that continue to accumulate in brain of mdr1a (-/-) mice over a long time period despite decreasing blood levels (Mayer et al. 1996 ; Schinkel et al. 1995 , Schinkel et al. 1996 ), suggesting the presence of an active digoxin uptake system at the BBB.

Recently, a novel multispecific organic anion transporting polypeptide (Oatp2) with an exceptionally high affinity for digoxin (K_m ~0.24 µM) has been cloned from rat brain (Noe et al. 1997 ). Oatp2 belongs to a growing family of multispecific drug transporters that are also expressed in liver and kidney, indicating that they play an important role in overall drug disposition (Meier et al. 1997 ). The best-characterized member of the Oatp gene family of membrane transporters is Oatp1, which represents an ~80-kD protein (Bergwerk et al. 1996 ), accepts a broad range of amphipathic substrates, including bile acids, steroid and glutathione conjugates, organic anionic dyes, leukotriene C4, GSH, peptidomimetic drugs, and even certain organic cations (Meier et al. 1997 ; Li et al. 1998 ), functions as an X^-/HCO₃^- and/or X^-/glutathione (GSH) antiporter (Satlin et al. 1997 ; Li et al. 1998 ), and is localized at the basolateral plasma membrane domain of hepatocytes (Bergwerk et al. 1996 ), the brush border of kidney S3 tubular epithelial cells (Bergwerk et al. 1996 ), and the apical plasma membrane of the choroid plexus (Angeletti et al. 1997 ). In contrast, the exact cellular localization of Oatp2 has not yet been determined. This study demonstrates that Oatp2 is expressed at BBB endothelial cells and at the basolateral pole of choroid plexus epithelial cells, indicating that it may participate in the active exchange of drugs (e.g., digoxin) between the brain interstitium, the cerebrospinal fluid, and the blood plasma compartments.

	Materials and Methods

Top Summary Introduction Materials and Methods Results Discussion Literature Cited

Animals
Male Sprague–Dawley rats (SUT:SDT) weighing 200–250 g were obtained from the Institute für Labortierkunde, University of Zurich (Zurich, Switzerland) and kept under standard conditions.

Riboprobes
Full-length antisense and sense Oatp2 cRNAs were labeled with digoxigenin. The 3.6-kb long probes were transcribed in vitro from an Oatp2 cDNA ligated into the Uni-ZAP XR vector (Noe et al. 1997 ). The vector was first linearized with restriction enzymes and transcribed with T7 or T3 RNA polymerases for antisense and sense probes, respectively. The transcription process was carried out with the nonradioactive RNA labeling kit (Boehringer; Mannheim, Germany) according to the manufacturer's recommendations. The transcripts were later shortened by limited alkaline hydrolysis to 200–250 nucleotide fragments (Cox et al. 1984 ).

Antibodies and Western Blotting
Antisera were raised in rabbits against a fusion protein containing the last 40 amino acids of Oatp1 (Eckhardt et al. 1999 ) and against a synthetic peptide consisting of the 15 terminal amino acids at the carboxy terminus of Oatp2 (648–662) coupled to KLH (keyhole limpet hemocyanin). Rabbits were immunized as described (Stieger et al. 1994 ). Western blots were performed with basolateral rat liver plasma membranes for Oatp1 (Eckhardt et al. 1999 ) and Oatp2 (Reichel et al. unpublished observations) and with crude rat brain membranes (see legend to Figure 1).

View larger version (49K): [in this window] [in a new window]   Figure 1. Western blot of crude rat brain membrane proteins with the Oatp2 antiserum. Crude rat brain membranes were isolated as described (Wenzel et al. 1997 ). Membrane proteins were separated on 7.5% SDS-polyacrylamide minigels (30 µg protein per lane) and transferred to nitrocellulose membranes. Blots were blocked for 1 hr at RT in 10 mM Tris (pH 8.0), 150 mM NaCl, and 0.05% Tween (TBST) containing 5% blocker (nonfat dry milk; Bio-Rad). Blots were then incubated overnight at 4C with native Oatp2 antiserum (dilution of 1:5000 in TBST containing 5% blocker) (left lane) or with Oatp2-antiserum preincubated with 10 µg/ml of the peptide used for immunization (preabsorption of antibodies) (right lane). Blots were washed three times with 20 mM Tris (pH 7.5), 60 mM NaCl, 2 mM EDTA, 0.4% Triton X-100, 0.4% deoxycholate, and three times with TBST. They were then incubated with horseradish peroxidase-conjugated goat anti-rabbit IgG (Pierce; Rockford, IL) diluted at 1:5000 for 1 hr at RT. Immunoreactivity was visualized with the enhanced chemiluminescence method (NEN Life Science Products; Boston, MA) according to standard procedures.

In Situ Hybridization Histochemistry (ISHH)
After decapitation of the animals the brains were removed and frozen immediately on dry ice. Cryostat sections (12 µm) were mounted on glass slides coated with 3-aminopropyltriethoxysilane (Sigma; St Louis, MO) and stored at -80C until use. The sections were fixed with 2% paraformaldehyde in PBS for 20 min, acetylated in 0.1 M triethanolamine hydrochloride containing 0.25% acetic anhydride, and prehybridized for 2–3 hr at room temperature (RT) with hybridization buffer containing 50% formamide, 5 x standard saline citrate (SSC), 5 x Denhardt's solution, 250 µg/ml yeast tRNA, and 500 µg/ml hering sperm DNA. Then the sections were hybridized overnight at 53C with the digoxigenin-labeled antisense or sense probe dissolved in the hybridization buffer at a concentration of about 1 µg/ml. Sections were then sequentially washed at 53C with SSC, using a final concentration of 0.1 x SSC/50% formamide for 20 min. Thereafter, the sections were processed for immunodetection with anti-DIG–alkaline phosphatase (Boehringer) and with nitrotetrazolium blue and X-phosphate as the color substrate (Boehringer) according to the manufacturer's instructions. Sections were incubated at RT for 1 h with the anti-DIG–alkaline phosphatase at a dilution of 1:5000 in 100 mM Tris-HCl (pH 7.5), 150 mM NaCl, and 1% blocking reagent. After several washings, additional incubations were performed with nitrotetrazolium blue/X-phosphate at a dilution of 1:50 and 1 mM levamisole (Sigma) in 100 mM Tris-HCl (pH 9.5), 100 mM NaCl, and 50 mM MgCl₂ at RT overnight in the dark.

Immunofluorescence Staining
To more definitively localize Oatp2 in brain capillary endothelial cells, cryostat sections subjected to ISHH analysis were also processed for immunofluorescence labeling with antibodies against von Willebrand factor (vWF; Sigma), an endothelial cell marker, and against glial fibrillary acidic protein (GFAP; Dako, Glostrup, Denmark), a marker for astrocytes. The sections were incubated overnight at 4C with the perspective antibody diluted in PBS containing 2% normal goat serum and 0.2% Triton X-100. The concentration of the rabbit anti-vWF was 1:400 and for the mouse anti-GFAP 1:5000. Finally, the sections were washed with PBS and incubated for 30 min at RT with the Cy3-labeled secondary antibody (1:300) (Jackson Immunoresearch; West Grove, PA).

Immunoperoxidase Staining
Rats were anesthetized with sodium pentobarbital (40 mg/kg IP). Brains were fixed with 2% paraformaldehyde and 15% of a saturated solution of picric acid in phosphate buffer (0.15 M, pH 7.4) through the ascending aorta. They were then removed, postfixed at 4C for 4 hr in the same fixative, and stored overnight at 4C in PBS containing 10% dimethylsulfoxide for cryoprotection. Sections of 40 µm were cut with a sliding microtome and collected in PBS. The sections were incubated overnight at 4C with the Oatp2 antiserum diluted at 1:20,000 in Tris–saline (pH 7.4) containing 2% normal serum and 0.2% Triton X-100. Then, they were washed in Tris–saline and stained with the ABC immunoperoxidase method using the Vectastain Elite kit (Vector Laboratories; Burlingame, CA) and diaminobenzidine hydrochloride as the chromogen. In some experiments, 12-µm cryostat sections were also used. They were fixed with 2% paraformaldehyde for 20 min and incubated with Oatp2 antiserum at a dilution of 1:5000.

Double Immunofluorescence Staining
Fresh-frozen and paraformaldehyde (2%)-fixed (20 min) cryostat sections (12 µm) were incubated overnight at 4C in PBS containing 2% normal serum, 0.2% Triton X-100, and the primary antibodies against Oatp1 (1:500), Oatp2 (1:5000), GFAP (1:5000), (₁-subunit of Na,K-ATPase (2 µg/ml; Upstate Biotechnology, Lake Placid, NY), and the P-glycoprotein (antibody C219, 1:50; Signet Laboratories, Dedham, MA). After washing in PBS, the sections were incubated at RT with affinity-purified secondary goat antibodies (Jackson Immunoresearch) labeled with Cy2 (1:100) and Cy3 (1:300). The immunofluorescently stained sections were analyzed by confocal laser microscopy (MRC 600; Bio-Rad Laboratories, Hercules, CA) using dual-channel illumination with simultanous image recording for the two different fluorochromes. The pictures were processed by IMARIS software (Bitplane; Zurich, Switzerland). Control experiments for anti-Oatp2 specificity were performed by preincubating the antibody with increasing concentrations (3–5 µg/ml) of the peptide used for immunization. To control for crossreactivity by the secondary antibodies, one of the primary antibodies was omitted during the incubation.

	Results

Top Summary Introduction Materials and Methods Results Discussion Literature Cited

Immunoblot Analysis of the Oatp2 Antiserum
As shown in Figure 1, the developed Oatp2 antiserum reacted with two narrow protein bands of crude rat brain membranes (Figure 1, left lane). However, whereas the 66-kD protein remained constant, the 76-kD protein band disappeared after preabsorption of the Oatp2 antibody in the presence of an excess of the oligopeptide used for immunization (Figure 1, right lane). A similar narrow 76-kD brain Oatp2 protein band has very recently also been reported by others using a different antibody (Kakyo et al. 1999 ). Furthermore, our Oatp2 antiserum did not recognize Oatp1 in separate Western blot analysis of rat liver basolateral plasma membrane proteins, and both Oatp1 and Oatp2 demonstrated a distinct distribution pattern in immunofluorescent studies of rat liver (Eckhardt et al. 1999 ; Reichel et al. unpublished observations). Taken together, these data strongly indicate that the antiserum raised is specific for Oatp2. Furthermore, the close correspondence between the size of the immunodetected brain Oatp2 and the theoretical molecular mass calculated from the originally cloned Oatp2 (~73 kD; Noe et al. 1997 ) suggests that glycosylation of the native brain Oatp2 is minor.

Localization of Oatp2 in Brain Capillary Endothelial Cells
We first used ISHH to localize Oatp2 mRNA in rat brain tissue. As shown in Figure 2A–2C, positive hybridization signals were associated exclusively with endothelial cells of cerebral capillaries. In contrast to the antisense probe, no positive hybridization signal was obtained with the sense probe (Figure 2A, inset), thus supporting the specific reactivity of the antisense riboprobe with Oatp2 mRNA. The ISHH-positive capillary endothelial cells were scattered diffusely over all brain regions, with the exception of the pineal gland, pituitary gland, subfornical organ, median eminance, and choroid plexus (not shown). Similar results were obtained at the protein level, where the Oatp2 antibody also selectively reacted with the capillary endothelium (Figure 2D and Figure 2E). Finally, after preabsorption of the Oatp2 antiserum with the antigenic peptide used for immunization, the immunopositive reactivity of the brain capillary endothelium was completely lost (Figure 2F), again demonstrating the specificity of the Oatp2 antiserum and supporting the idea that the preabsorption sensitive 76-kD protein band in Figure 1 corresponds to Oatp2 in brain capillary endothelium cells.

View larger version (135K): [in this window] [in a new window]   Figure 2. Localization of Oatp2 in rat brain capillary endothelial cells by nonradioactive ISH (A–C) and immunohistochemistry (D,E). Sections of cerebral cortex (A) and hippocampal formation (B,C) were hybridized with the digoxigenin-labeled antisense probe for Oatp2 mRNA. Inset in A shows an adjacent control section hybridized with the sense probe. (D) Immunoperoxidase staining of the hippocampal formation with the Oatp2 antibody. (E) Higher magnification of immunopositive brain capillary endothelial cells. (F) Negative immunostaining after preabsorption of the Oatp2 antiserum with the antigenic peptide used for immunization. GC, granular cell layer. Bars: A = 100 µm; B,D,F = 40 µm; C = 25 µm; E = 10 µm.

To more definitely discriminate between Oatp2 expression in capillary endothelial cells and in astrocytes, double labeling experiments were performed that combined in situ hybridization for Oatp2 mRNA with immunofluorescence staining for the endothelial marker vWF or the astrocyte marker GFAP. These experiments revealed that most, if not all, cells expressing Oatp2 mRNA were immunopositive for vWF and vice versa (Figure 3A) and that positivity for Oatp2 mRNA did not correlate with immunopositivity for GFAP, indicating that astrocytes do not express Oatp2 (Figure 3B). In addition, double immunofluorescence staining with Oatp2 and GFAP antibodies combined with confocal microscopic analysis indicated that Oatp2 is localized on both the abluminal and the luminal domain of brain capillary endothelial cells (Figure 3C–3F). Furthermore, Figure 3E shows the intimate contacts between the brain capillaries and the surrounding GFAP-positive astrocyte endings that serve as ideal markers for the brain side of the blood vessels. In contrast, the blood-oriented luminal side of brain capillary endothelium is characterized by its expression of mdr1a or P-glycoprotein (Stewart et al. 1996 ; Beaulieu et al. 1997 ). With the P-glycoprotein antibody C219, Figure 3F confirms that P-glycoprotein is selectively expressed at the luminal membrane, whereas Oatp2 is localized on the entire surface domain of brain capillary endothelial cells. However, it should be noted that additional localization of Oatp2 in intracellular vesicles of endothelial cells cannot be excluded at present.

View larger version (97K): [in this window] [in a new window]   Figure 3. Cellular localization of Oatp2 by double labeling techniques combining ISH and immunofluorescence staining. All pictures were analyzed by confocal laser microscopy and superimposition of the digitalized images. (A,B) The black color represents the hybridization signal of the Oatp2 mRNA and the red color depicts the immunopositivity for the endothelial marker vWF (A) and the astrocyte marker GFAP (B). (C–E) Double immunostaining with the antibodies to Oatp2 (red) and to GFAP (green). Oatp2 is expressed only in endothelial cells and not in astrocytes. GFAP immunoreactivity indicates the brain (abluminal) side of the capillary endothelium. (F) Double immunostaining (yellow) of brain endothelial cells with antibodies to Oatp2 (red) and to P-glycoprotein (C219; green). Whereas P-glycoprotein is selectively localized on the luminal side, Oatp2 is present on the entire surface of rat brain endothelial cells. Bars = 10 µm.

Localization of Oatp2 Compared to Oatp1 in Choroid Plexus Epithelial Cells
Oatp2 mRNA was also detected in the choroid plexus. However, in contrast to the BBB capillary endothelium, Oatp2 mRNA (Figure 4A) and Oatp2 protein (Figure 4B) were detected only in choroid plexus epithelial cells. Moreover, the immunofluorescence staining indicated that Oatp2 is selectively expressed at the basolateral pole of choroid plexus epithelial cells (Figure 4B). This basolateral Oatp2 expression is further shown in Figure 5, in which the apical membrane of the choroid plexus epithelial cells was selectively labeled with an antibody against the ₁-subunit of the Na,K-ATPase (Marrs et al. 1993 ). In contrast to the apical co-localization of Na,K-ATPase and Oatp1 (Figure 5F) (Angeletti et al. 1997 ), Oatp2 immunoreactivity was localized to the opposite cell pole of choroid plexus epithelial cells (Figure 5A and Figure 5C). Therefore, the basolateral Oatp2 staining most probably represents the interdigitated basolateral plasma membrane of choroid plexus epithelial cells, although additional localization of Oatp2 in intracellular vesicles cannot be excluded at this level of magnification. Nevertheless, the polar localization of Oatp1 and Oatp2 in choroid plexus epithelial cells again demonstrates the specificity of the antibodies used and contrasts to their expression in the liver, in which they are both localized at the basolateral plasma membrane of hepatocytes (Eckhardt et al. 1999 ; Kakyo et al. 1999 ; Reichel et al. unpublished observations).

View larger version (122K): [in this window] [in a new window]   Figure 4. Localization of Oatp2 in the choroid plexus. (A) ISH with the antisense probe for Oatp2 mRNA. (B) Immunofluorescence staining for Oatp2. The boxed area has been enlarged to indicate more clearly the putative selective basolateral expression of Oatp2. Arrow points to the apical membrane of epithelial cells. Bar = 20 µm.

View larger version (77K): [in this window] [in a new window]   Figure 5. Polar expression of Oatp2 (A–C) and Oatp1 (D–F) at choroid plexus epithelial cells, as visualized by their double fluorescence staining with the apically localized 1-subunit of Na,K-ATPase (Marrs et al. 1993 ). (A) Staining for Oatp2. (B,E) Staining for Na,K-ATPase. (C) Superimposition of A and B showing localization of Oatp2 (red) at the opposite (basolateral) cell pole compared to Na,K-ATPase (green). (D) Staining for Oatp1. (F) Superimposition of D and E showing co-localization of Oatp1 and Na,K-ATPase at the apical plasma membrane of choroid plexus epithelial cells (yellow). Bars = 10 µm.

	Discussion

Top Summary Introduction Materials and Methods Results Discussion Literature Cited

This study, for the first time, localizes the multispecific organic anion transporter Oatp2 at the BBB and demonstrates a polar distribution of Oatp1 and Oatp2 in the choroid plexus epithelium.

The BBB barrier is formed by a tight endothelium lining the cerebral microvessels. Effective tight junctions restrict solute uptake across the paracellular pathway to small water-soluble compounds and make transcellular routes necessary for uptake of larger organic solutes into brain tissue. These transcellular routes have been divided into a diffusional pathway for lipid-soluble agents, specific transport systems for essential nutrients such as glucose, amino acids, and purines, and receptor-mediated and adsorptive endocytosis for hormones and plasma proteins, respectively (Abbott and Romero 1996 ). Although passive diffusion can account for brain penetration of many nonionic very lipid-soluble drugs, ionized compounds require carrier-mediated translocation across the plasma membrane of the BBB endothelium (Spector 1990 ). Our study demonstrates that in addition to the "renal-like" p-aminohippurate system (Wong et al. 1993 ), the BBB endothelium also localizes the "liver-like" organic anion carrier Oatp2 (Figure 2 and Figure 3). This polyspecific transporter can mediate transmembrane transport of a wide range of amphipathic substrates, including many drugs, drug conjugates, and small peptides (Meier et al. 1997 ; Noe et al. 1997 ; Kakyo et al. 1999 ). Its high expression at the surface of BBB endothelial cells (Figure 3), together with its high affinity for the cardiac glycoside digoxin (Noe et al. 1997 ), indicates that Oatp2 might be responsible for the extensive intracerebral accumulation of digoxin in brain tissue of mdr1a (-/-) knockout mice (Mayer et al. 1996 ; Schinkel et al. 1995 , Schinkel et al. 1996 ). Furthermore, Oatp2 appears to mediate uptake of certain centrally active peptides, such as the ₁-opioid receptor agonist [D-Pen²,D-Pen²] enkephalin across the BBB (Kakyo et al. 1999 ). Hence, Oatp2 may represent an important influx system at the BBB for a wide range of amphipathic substrates, while the P-gp mediates rapid unidirectional efflux of potentially neurotoxic compounds.

Interestingly, Oatp2 is also localized at the basolateral cell pole of choroid plexus epithelial cells (Figure 4 and Figure 5). The polar localization of Oatp1 and Oatp2 at the apical and basolateral surface domains, respectively, indicates that these two transporters may serve complementary functions in the transport of amphipathic organic anions into and/or out of the cerebrospinal fluid. Previous in vitro studies have provided evidence for the presence of at least one "liver-like" organic anion transporter in the choroid plexus of mammalian brain (Barany 1973a ). Interestingly, the transport kinetics and substrate specificity of this(these) "liver-like" transport system(s) (Barany 1973b , Barany 1975 ) correspond closely to the transport properties of Oatp1 and Oatp2 (Meier et al. 1997 ; Noe et al. 1997 ; Kakyo et al. 1999 ), indicating that these Oatps are responsible for "liver-like" transport properties of choroid plexus epithelial cells. Furthermore, because Oatp1 mediates low-affinity transport of GSH and high-affinity transport of leukotriene C4 (Li et al. 1998 ), it could be involved in the apical secretion of GSH into CSF (Anderson et al. 1989 ) in exchange for leukotriene C4 uptake from cerebrospinal fluid (Spector and Johanson 1989 ). Whether and to what degree Oatp2 exhibits similar efflux and/or uptake functions at the basolateral plasma membrane of choroid plexus epithelial cells remains to be determined.

In contrast to a recent study by Abe and co-workers (1998), we found no evidence for expression of Oatp2 mRNA in hippocampal neuronal cells (Figure 2). A similar discrepancy between their study and ours also exists with respect to Oatp2 mRNA expression in the cerebellar cortex (our negative data; not shown). The most probable cause of these discrepancies lies in the different ISHH methodology used. Whereas Abe and co-workers used a radiolabeled antisense cRNA probe, we used a digoxigenin-labeled antisense probe and a different ISH protocol. It is noteworthy, however, that in preliminary experiments with a radiolabeled probe we also found strong positivity in hippocampal and cerebellar neuronal cells. This neuronal labeling was judged as unspecific because similar positive labeling was also found with the sense probe. Furthermore, the neuronal cell labeling collapsed with the digoxigenin-labeled antisense probe, whereas the strong labeling of the brain capillary and choroid plexus epithelial cells remained constant independently of the labeling methods used. Finally, no immunopositivity of hippocampal and/or cerebellar neuronal cells was found with the Oatp2 antiserum used. Hence, although this study presents strong evidence for Oatp2 expression in the brain capillary endothelium and in the choroid plexus epithelium at both the mRNA and the protein level, definitive demonstration of additional expression of Oatp2 in neuronal cells requires further investigation.

In conclusion, we have localized Oatp2 at the BBB endothelium and demonstrate a polar distribution of Oatp1 and Oatp2 at the apical and basolateral cell poles of choroid plexus epithelial cells. At both sites, the expression of members of the Oatp gene family of membrane transporters can explain some phenotypic transport activities previously identified in functional in vivo and in vitro studies. The results demonstrate that more carriers than hitherto assumed (Abbott and Romero 1996 ) exist at the BBB and in the choroid plexus for amphipathic organic anion and drug transport into and out of the brain and the cerebrospinal fluid, respectively. Because these carriers must be taken into account in the targeting of therapeutic drugs to the brain tissue, further delineation of the exact functional role, directionality of transport, and structure/activity relationships of Oatp1 and Oatp2 under various physiological and pathophysiological conditions is important for a better understanding of their "gatekeeping" functions at their strategic localization between the blood and brain compartments.

	Acknowledgments

Supported by the Swiss National Science Foundation (grant 31-045536.95) and the Olga Mayenfisch Foundation, Zurich, Switzerland.

We thank Dr H.U. Luder for allowing us to use the technical facilities of the Division of Oral Structural Biology of the University Centre for Dental Medicine, Zurich, Switzerland.

Received for publication December 4, 1998; accepted April 20, 1999.

	Literature Cited

Top Summary Introduction Materials and Methods Results Discussion Literature Cited

Abbott NJ, Romero IA (1996) Transporting therapeutics across the blood-brain barrier. Mol Med Today 2:106-113[Medline]

Abe T, Kakyo M, Sakagami H, Tokui T, Nishio T, Tanemoto M, Nomura H, Hebert SC, Matsuno S, Kondo H, Yawo H (1998) Molecular characterization and tissue distribution of a new organic anion transporter subtype (oatp3) that transports thyroid hormones and taurocholate and comparison with oatp2. J Biol Chem 273:22395-22401[Abstract/Free Full Text]

Anderson ME, Underwood M, Bridges RJ, Meister A (1989) Glutathione metabolism at the blood-cerebrospinal fluid barrier. FASEB J 3:2527-2531[Abstract]

Angeletti RH, Novikoff PM, Juvvadi SR, Fritschy JM, Meier PJ, Wolkoff AW (1997) The choroid plexus epithelium is the site of the organic anion transport protein in the brain. Proc Natl Acad Sci USA 94:283-286[Abstract/Free Full Text]

Barany EH (1973a) The liver-like anion transport system in rabbit kidney, uvea and choroid plexus. I. Selectivity of some inhibitors, direction of transport, possible physiological substrates. Acta Physiol Scand 88:412-429[Medline]

Barany EH (1973b) The liver-like anion transport system in rabbit kidney, uvea and choroid plexus. II. Efficiency of acidic drugs and other anions as inhibitors. Acta Physiol Scand 88:491-504[Medline]

Barany EH (1975) In vitro uptake of bile acids by choroid plexus, kidney cortex and anterior uvea. I. The iodipamide-sensitive transport systems in the rabbit. Acta Physiol Scand 93:250-268[Medline]

Beaulieu E, Demeule M, Ghitescu L, Béliveau R (1997) P-Glycoprotein is strongly expressed in the luminal membranes of the endothelium of blood vessels in the brain. Biochem J 326:539-544

Bergwerk AJ, Shi X, Ford AC, Kanai N, Jacquemin E, Burk RD, Bai S, Novikoff PM, Stieger B, Meier PJ, Schuster VL, Wolkoff AW (1996) Immunologic distribution of an organic anion transport protein in rat liver and kidney. Am J Physiol 271:G231-238[Abstract/Free Full Text]

Cox KH, DeLeon DV, Angerer LM, Angerer RC (1984) Detection of mRNAs in sea urchin embryos by in situ hybridization using asymmetric RNA probes. Dev Biol 101:485-502[Medline]

Eckhardt U, Schroeder A, Stieger B, Höchli M, Tynes R, Meier PJ, Hagenbuch B (1999) Polyspecific substrate transport by the hepatic organic anion transporter oatp1 in stably transfected CHO cells. Am J Physiol 276:G1037-1042[Abstract/Free Full Text]

Kakyo M, Sakagami H, Nishio T, Nakai D, Nakagomi R, Tokui T, Naitoh T, Matsuno S, Abe T, Yawo H (1999) Immunohistochemical distribution and functional characterization of an organic anion transporting polypeptide 2 (Oatp2). FEBS Lett 445:343-346[Medline]

Kannan R, Kuhlenkamp JF, Jeandidier E, Trinh H, Ookhtens M, Kaplowitz N (1990) Evidence for carrier-mediated transport of glutathione across the blood-brain barrier in the rat. J Clin Invest 85:2009-2013

Kannan R, Kuhlenkamp JF, Ookhtens M, Kaplowitz N (1992) Transport of glutathione in blood-brain barrier of the rat: inhibition by glutathione analogs and age-dependence. J Pharmacol Exp Ther 263:964-970[Abstract/Free Full Text]

Li L, Lee TK, Meier PJ, Ballatori N (1998) Identification of glutathione as a driving force and leukotriene C4 as a substrate for oatp1, the hepatic sinusoidal organic solute transporter. J Biol Chem 273:16184-16191[Abstract/Free Full Text]

Marrs JA, Napolitano EW, Murphy–Erdosh C, Mays RW, Reichardt LF, Nelson WJ (1993) Distinguishing roles of the membrane-cytoskeleton and cadherin mediated cell-cell adhesion in generating different Na⁺,K⁺-ATPase distributions in polarized epithelia. J Cell Biol 123:149-164[Abstract/Free Full Text]

Mayer U, Wagenaar E, Beijnen JH, Smit JW, Meijer DK, van Asperen J, Borst P, Schinkel AH (1996) Substantial excretion of digoxin via the intestinal mucosa and prevention of long-term digoxin accumulation in the brain by the mdr 1a P-glycoprotein. Br J Pharmacol 119:1038-1044[Medline]

Meier PJ, Eckhardt U, Schroeder A, Hagenbuch B, Stieger B (1997) Substrate specificity of sinusoidal bile acid and organic anion uptake systems in rat and human liver. Hepatology 26:1667-1677[Medline]

Noé B, Hagenbuch B, Stieger B, Meier PJ (1997) Isolation of a multispecific organic anion and cardiac glycoside transporter from rat brain. Proc Natl Acad Sci USA 94:10346-10350[Abstract/Free Full Text]

Satlin LM, Amin V, Wolkoff AW (1997) Organic anion transporting polypeptide mediates organic anion/HCO₃^- exchange. J Biol Chem 272:26340-26345[Abstract/Free Full Text]

Schinkel AH, Wagenaar E, Mol CA, van Deemter L (1996) P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J Clin Invest 97:2517-2524[Medline]

Schinkel AH, Wagenaar E, van Deemter L, Mol CA, Borst P (1995) Absence of the mdr1a P-glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. J Clin Invest 96:1698-1705

Spector R (1990) Drug transport in the central nervous system: role of carriers. Pharmacology 40:1-7[Medline]

Spector R, Johanson CE (1989) The mammalian choroid plexus. Sci Am 261:68-74[Medline]

Stewart PA, Béliveau R, Rogers KA (1996) Cellular localization of P-glycoprotein in brain versus gonadal capillaries. J Histochem Cytochem 44:679-685[Abstract]

Stieger B, Hagenbuch B, Landmann L, Höchli M, Schroeder A, Meier PJ (1994) In situ localization of the hepatocytic Na⁺/taurocholate cotransporting polypeptide in rat liver. Gastroenterology 107:1781-1787[Medline]

Wenzel A, Fritschy JM, Mohler H, Benke D (1997) NMDA receptor heterogeneity during postnatal development of the rat brain: differential expression of the NR2A, NRB, and NR2C subunit proteins. J Neurochem 68:469-478[Medline]

Wong SL, Van Belle K, Sawchuk RJ (1993) Distributional transport kinetics of zidovudine between plasma and brain extracellular fluid/cerebrospinal fluid in the rabbit: investigation of the inhibitory effect of probenecid utilizing microdialysis. J Pharmacol Exp Ther 264:899-909[Abstract/Free Full Text]

Zlokovic BV, Mackic JB, McComb JG, Weiss MH, Kaplowitz N, Kannan R (1994) Evidence for transcapillary transport of reduced glutathione in vascular perfused guinea-pig brain. Biochem Biophys Res Commun 201:402-408[Medline]

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				E. Kilic, A. Spudich, U. Kilic, K. M. Rentsch, R. Vig, C. M. Matter, H. Wunderli-Allenspach, J.-M. Fritschy, C. L. Bassetti, and D. M. Hermann ABCC1: a gateway for pharmacological compounds to the ischaemic brain Brain, October 1, 2008; 131(10): 2679 - 2689. [Abstract] [Full Text] [PDF]

				D. S. Miller, B. Bauer, and A. M. S. Hartz Modulation of P-Glycoprotein at the Blood-Brain Barrier: Opportunities to Improve Central Nervous System Pharmacotherapy Pharmacol. Rev., June 1, 2008; 60(2): 196 - 209. [Abstract] [Full Text] [PDF]

				B. M. Johnson, P. Zhang, J. D. Schuetz, and K. L. R. Brouwer CHARACTERIZATION OF TRANSPORT PROTEIN EXPRESSION IN MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN (MRP) 2-DEFICIENT RATS Drug Metab. Dispos., April 1, 2006; 34(4): 556 - 562. [Abstract] [Full Text] [PDF]

				B. Kis, T. Isse, J. A. Snipes, L. Chen, H. Yamashita, Y. Ueta, and D. W. Busija Effects of LPS stimulation on the expression of prostaglandin carriers in the cells of the blood-brain and blood-cerebrospinal fluid barriers J Appl Physiol, April 1, 2006; 100(4): 1392 - 1399. [Abstract] [Full Text] [PDF]

				B. Bauer, A. M. S. Hartz, G. Fricker, and D. S. Miller Modulation of p-Glycoprotein Transport Function at the Blood-Brain Barrier Experimental Biology and Medicine, February 1, 2005; 230(2): 118 - 127. [Abstract] [Full Text] [PDF]

				Y.-J. Lee, H. Kusuhara, J. W. Jonker, A. H. Schinkel, and Y. Sugiyama Investigation of Efflux Transport of Dehydroepiandrosterone Sulfate and Mitoxantrone at the Mouse Blood-Brain Barrier: A Minor Role of Breast Cancer Resistance Protein J. Pharmacol. Exp. Ther., January 1, 2005; 312(1): 44 - 52. [Abstract] [Full Text] [PDF]

				R. Kikuchi, H. Kusuhara, T. Abe, H. Endou, and Y. Sugiyama Involvement of Multiple Transporters in the Efflux of 3-Hydroxy-3-methylglutaryl-CoA Reductase Inhibitors across the Blood-Brain Barrier J. Pharmacol. Exp. Ther., December 1, 2004; 311(3): 1147 - 1153. [Abstract] [Full Text] [PDF]

				Y. Zhang, J. D. Schuetz, W. F. Elmquist, and D. W. Miller Plasma Membrane Localization of Multidrug Resistance-Associated Protein Homologs in Brain Capillary Endothelial Cells J. Pharmacol. Exp. Ther., November 1, 2004; 311(2): 449 - 455. [Abstract] [Full Text] [PDF]

				C. M. Breen, D. B. Sykes, C. Baehr, G. Fricker, and D. S. Miller Fluorescein-methotrexate transport in rat choroid plexus analyzed using confocal microscopy Am J Physiol Renal Physiol, September 1, 2004; 287(3): F562 - F569. [Abstract] [Full Text] [PDF]

				D. Sykes, D. H. Sweet, S. Lowes, S. K. Nigam, J. B. Pritchard, and D. S. Miller Organic anion transport in choroid plexus from wild-type and organic anion transporter 3 (Slc22a8)-null mice Am J Physiol Renal Physiol, May 1, 2004; 286(5): F972 - F978. [Abstract] [Full Text] [PDF]

				S. Choudhuri, N. J. Cherrington, N. Li, and C. D. Klaassen CONSTITUTIVE EXPRESSION OF VARIOUS XENOBIOTIC AND ENDOBIOTIC TRANSPORTER mRNAs IN THE CHOROID PLEXUS OF RATS Drug Metab. Dispos., November 1, 2003; 31(11): 1337 - 1345. [Abstract] [Full Text] [PDF]

				D. Sugiyama, H. Kusuhara, H. Taniguchi, S. Ishikawa, Y. Nozaki, H. Aburatani, and Y. Sugiyama Functional Characterization of Rat Brain-specific Organic Anion Transporter (Oatp14) at the Blood-Brain Barrier: HIGH AFFINITY TRANSPORTER FOR THYROXINE J. Biol. Chem., October 31, 2003; 278(44): 43489 - 43495. [Abstract] [Full Text] [PDF]

				J. E. Gibbs, T. Rashid, and S. A. Thomas Effect of Transport Inhibitors and Additional Anti-HIV Drugs on the Movement of Lamivudine (3TC) across the Guinea Pig Brain Barriers J. Pharmacol. Exp. Ther., September 1, 2003; 306(3): 1035 - 1041. [Abstract] [Full Text] [PDF]

				N. Mizuno, T. Niwa, Y. Yotsumoto, and Y. Sugiyama Impact of Drug Transporter Studies on Drug Discovery and Development Pharmacol. Rev., September 1, 2003; 55(3): 425 - 461. [Abstract] [Full Text] [PDF]

				R. Kikuchi, H. Kusuhara, D. Sugiyama, and Y. Sugiyama Contribution of Organic Anion Transporter 3 (Slc22a8) to the Elimination of p-Aminohippuric Acid and Benzylpenicillin across the Blood-Brain Barrier J. Pharmacol. Exp. Ther., July 1, 2003; 306(1): 51 - 58. [Abstract] [Full Text] [PDF]

				T. Suzuki, T. Onogawa, N. Asano, H. Mizutamari, T. Mikkaichi, M. Tanemoto, M. Abe, F. Satoh, M. Unno, K. Nunoki, et al. Identification and Characterization of Novel Rat and Human Gonad-Specific Organic Anion Transporters Mol. Endocrinol., July 1, 2003; 17(7): 1203 - 1215. [Abstract] [Full Text] [PDF]

				M. Trauner and J. L. Boyer Bile Salt Transporters: Molecular Characterization, Function, and Regulation Physiol Rev, April 1, 2003; 83(2): 633 - 671. [Abstract] [Full Text] [PDF]

				W. M. Pardridge BLOOD-BRAIN BARRIER DRUG TARGETING: THE FUTURE OF BRAIN DRUG DEVELOPMENT Mol. Interv., March 1, 2003; 3(2): 90 - 105. [Abstract] [Full Text] [PDF]

				S. Ohtsuki, T. Takizawa, H. Takanaga, N. Terasaki, T. Kitazawa, M. Sasaki, T. Abe, K.-i. Hosoya, and T. Terasaki In Vitro Study of the Functional Expression of Organic Anion Transporting Polypeptide 3 at Rat Choroid Plexus Epithelial Cells and Its Involvement in the Cerebrospinal Fluid-to-Blood Transport of Estrone-3-Sulfate Mol. Pharmacol., March 1, 2003; 63(3): 532 - 537. [Abstract] [Full Text] [PDF]

				B. Hagenbuch, B. Gao, and Peter. J. Meier Transport of Xenobiotics Across the Blood-Brain Barrier Physiology, December 1, 2002; 17(6): 231 - 234. [Abstract] [Full Text] [PDF]

				D. H. Sweet, D. S. Miller, J. B. Pritchard, Y. Fujiwara, D. R. Beier, and S. K. Nigam Impaired Organic Anion Transport in Kidney and Choroid Plexus of Organic Anion Transporter 3 (Oat3 (Slc22a8)) Knockout Mice J. Biol. Chem., July 19, 2002; 277(30): 26934 - 26943. [Abstract] [Full Text] [PDF]

Y. Nagata, H. Kusuhara, H. Endou, and Y. Sugiyama Expression and Functional Characterization of Rat Organic Anion Transporter 3 (rOat3) in the Choroid Plexus Mol. Pharmacol., May 1, 2002; 61(5): 982 - 988. [Abstract] [Full Text] [PDF]